8-K: Kenvue Reports Full Year and Fourth Quarter 2024 Results; Provides Outlook for FY25

Kenvue's Q4 net sales decreased slightly by 0.1% to $3.7 billion, while full-year net sales increased by 0.1% to $15.5 billion, with the company providing its financial outlook for 2025.

Summary

• Kenvue announced its financial results for the full year and fourth quarter ended December 29, 2024.
• Fourth quarter net sales decreased 0.1% to $3.7 billion, but organic sales grew 1.7%.
• The organic sales growth was driven by a 1.0% value realization and 0.7% volume growth.
• Diluted EPS for Q4 was $0.15, while adjusted diluted EPS was $0.26.
• Full year net sales increased 0.1% to $15.5 billion, with organic sales growing 1.5%.
• The full year organic sales growth was driven by 2.7% value realization, partially offset by a 1.2% volume decline.
• Full year diluted EPS was $0.54, and adjusted diluted EPS was $1.14.
• The company is providing an outlook for fiscal year 2025, expecting net sales change of -1% to +1% year-over-year, with organic sales growth of +2% to +4%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are some negative aspects like decreased net sales in Q4 and volume decline for the full year, the company is projecting organic sales growth for the next fiscal year and has improved its gross profit margin. Management's comments are cautiously optimistic.

Positives

• Organic sales grew by 1.7% in Q4 and 1.5% for the full year, indicating underlying strength in the business.
• Gross profit margin expanded by 200 basis points for the full year, reflecting improved efficiency.
• The company is projecting organic sales growth of 2% to 4% for the next fiscal year.
• Value realization (price and mix) contributed positively to organic sales growth in both Q4 and the full year.

Negatives

• Net sales decreased slightly by 0.1% in Q4.
• Volume declined by 1.2% for the full year, offsetting some of the gains from value realization.
• Foreign currency headwinds impacted net sales by 1.8% in Q4 and 1.4% for the full year.
• Diluted EPS decreased from $0.17 to $0.15 in Q4 and from $0.90 to $0.54 for the full year.

Risks

• The company faces a foreign currency headwind of approximately 3% in the 2025 outlook.
• The 2025 outlook does not include any potential impacts from tariffs introduced in 2025.
• Weak incidences of cold, cough & flu led to a significant decline in the pediatric pain franchise in Self Care.
• Go-to-market disruption in Asia Pacific impacted the company's results, with an outsized impact on Essential Health.

Future Outlook

Kenvue expects net sales change of -1% to +1% year-over-year, with organic sales growth of +2% to +4% for fiscal year 2025; adjusted operating income margin improvement year-over-year; and flat to +2% year-over-year adjusted diluted earnings per share growth, including a mid-single-digit unfavorable impact from foreign currency.

Management Comments

• Thibaut Mongon, Chief Executive Officer, stated that Kenvue delivered on its 2024 profit commitments despite headwinds and enters 2025 as a more competitive company.
• Paul Ruh, Chief Financial Officer, mentioned that Kenvue expects to accelerate performance throughout the year while navigating the dynamic external environment.

Industry Context

Kenvue, as the world's largest pure-play consumer health company, is navigating a challenging environment with currency headwinds and fluctuating consumer behavior, while focusing on brand investment and operational efficiency to drive growth.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• A comparison would require detailed knowledge of the performance of Kenvue's direct competitors such as Haleon, Sanofi Consumer Healthcare, and Bayer Consumer Health.
• Key metrics to compare would include organic sales growth, gross profit margin, and adjusted operating income margin.
• Benchmarking against these companies would provide a clearer picture of Kenvue's relative performance.

Stakeholder Impact

• Shareholders may be concerned about the decrease in diluted EPS but encouraged by the projected organic sales growth.
• Employees may be affected by restructuring and cost-saving initiatives.
• Customers may benefit from increased brand investments and new product development.

Next Steps

• Kenvue will host a conference call with investors on February 6, 2025, to discuss the results.

Key Dates

Keywords

Kenvue, Financial Results, Net Sales, Organic Sales, EPS, Outlook, Consumer Health